64,400 Shares in The Oncology Institute, Inc. $TOI Bought by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC bought a new position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 64,400 shares of the company’s stock, valued at approximately $132,000. Kingswood Wealth Advisors LLC owned approximately 0.07% of Oncology Institute as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of TOI. XTX Topco Ltd boosted its stake in Oncology Institute by 49.5% during the first quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock worth $63,000 after acquiring an additional 18,448 shares in the last quarter. WealthShield Partners LLC bought a new position in Oncology Institute during the first quarter worth $80,000. Citizens Financial Group Inc. RI bought a new position in Oncology Institute during the first quarter worth $71,000. Josh Arnold Investment Consultant LLC bought a new position in Oncology Institute during the first quarter worth $2,267,000. Finally, Goldman Sachs Group Inc. acquired a new position in Oncology Institute during the first quarter worth $131,000. 36.86% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. B. Riley assumed coverage on shares of Oncology Institute in a report on Wednesday, July 16th. They set a “buy” rating and a $6.00 price objective on the stock. Noble Financial assumed coverage on shares of Oncology Institute in a report on Wednesday, July 23rd. They set an “outperform” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oncology Institute has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Oncology Institute Stock Performance

Shares of TOI stock opened at $3.79 on Monday. The firm has a 50-day moving average of $3.58 and a 200-day moving average of $2.96. The company has a market cap of $354.37 million, a P/E ratio of -5.57 and a beta of 0.08. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.62 and a quick ratio of 1.37. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $4.50.

Insider Activity at Oncology Institute

In other news, Director Growth I. L.P. M33 sold 681,832 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $2,106,860.88. Following the completion of the sale, the director owned 590,892 shares in the company, valued at $1,825,856.28. This represents a 53.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.50% of the stock is currently owned by corporate insiders.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.